Published in J Med Chem on December 30, 2004
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol (2009) 3.07
Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood (2009) 1.85
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood (2009) 1.82
Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood (2012) 1.75
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics (2009) 1.75
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther (2009) 1.73
The role of Src in solid tumors. Oncologist (2009) 1.72
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol (2010) 1.69
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis (2010) 1.64
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
SRC: a century of science brought to the clinic. Neoplasia (2010) 1.58
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene (2008) 1.57
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res (2010) 1.55
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis (2011) 1.53
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene (2011) 1.49
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev (2010) 1.49
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. PLoS Comput Biol (2009) 1.48
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma (2011) 1.47
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res (2009) 1.44
The challenge of developing robust drugs to overcome resistance. Drug Discov Today (2011) 1.43
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer (2009) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res (2009) 1.39
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol (2011) 1.38
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep (2007) 1.36
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol (2009) 1.29
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood (2009) 1.29
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol (2009) 1.24
Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res (2013) 1.23
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23
The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther (2010) 1.22
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol (2009) 1.18
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16
The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene (2009) 1.16
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer (2009) 1.15
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med (2008) 1.13
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res (2013) 1.12
Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One (2011) 1.12
Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene (2011) 1.11
Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene (2012) 1.11
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma (2008) 1.09
Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells. Assay Drug Dev Technol (2012) 1.09
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia (2010) 1.07
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett (2010) 1.06
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood (2007) 1.05
Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol Cancer Ther (2010) 1.04
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood (2011) 1.04
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. J Oncol (2009) 1.03
Evolution of therapies for chronic myelogenous leukemia. Cancer J (2011) 1.01
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer (2010) 1.01
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res (2012) 0.99
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J Neuroinflammation (2012) 0.98
Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag (2009) 0.98
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene (2011) 0.98
Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer (2011) 0.97
Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer (2010) 0.97
Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One (2012) 0.97
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol (2013) 0.97
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Automated ligand fitting by core-fragment fitting and extension into density. Acta Crystallogr D Biol Crystallogr (2006) 5.03
Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med (2007) 4.82
Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. Science (2012) 4.52
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Ciliary proteins link basal body polarization to planar cell polarity regulation. Nat Genet (2007) 3.79
Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem (2006) 3.75
Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science (2009) 3.69
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet (2008) 3.62
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A (2006) 3.48
Math1-driven GFP expression in the developing nervous system of transgenic mice. Gene Expr Patterns (2003) 3.42
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood (2007) 3.13
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Dishevelled genes mediate a conserved mammalian PCP pathway to regulate convergent extension during neurulation. Development (2006) 2.96
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A (2005) 2.85
Wnt5a functions in planar cell polarity regulation in mice. Dev Biol (2007) 2.85
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J Bacteriol (2003) 2.48
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol (2006) 2.37
Cryo-EM study of the chromatin fiber reveals a double helix twisted by tetranucleosomal units. Science (2014) 2.37
Regulation of polarized extension and planar cell polarity in the cochlea by the vertebrate PCP pathway. Nat Genet (2005) 2.36
Murine dishevelled 3 functions in redundant pathways with dishevelled 1 and 2 in normal cardiac outflow tract, cochlea, and neural tube development. PLoS Genet (2008) 2.29
Stephacidin A and B: two structurally novel, selective inhibitors of the testosterone-dependent prostate LNCaP cells. J Am Chem Soc (2002) 2.26
The role of barren stalk1 in the architecture of maize. Nature (2004) 2.15
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother (2005) 2.08
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J Biol Chem (2002) 2.06
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther (2008) 2.04
The control of spikelet meristem identity by the branched silkless1 gene in maize. Science (2002) 2.00
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol (2006) 1.95
Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med (2010) 1.94
Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium. J Biol Chem (2004) 1.92
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res (2007) 1.82
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med (2007) 1.77
A novel class of Helitron-related transposable elements in maize contain portions of multiple pseudogenes. Plant Mol Biol (2005) 1.73
Orientation within the exosporium and structural stability of the collagen-like glycoprotein BclA of Bacillus anthracis. J Bacteriol (2005) 1.71
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A (2013) 1.70
The Relationship between auxin transport and maize branching. Plant Physiol (2008) 1.68
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther (2006) 1.66
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
sparse inflorescence1 encodes a monocot-specific YUCCA-like gene required for vegetative and reproductive development in maize. Proc Natl Acad Sci U S A (2008) 1.64
The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep (2009) 1.64
Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev (2008) 1.64
Synthesis and electromagnetic, microwave absorbing properties of core-shell Fe3O4-poly(3, 4-ethylenedioxythiophene) microspheres. ACS Appl Mater Interfaces (2011) 1.62
Asymptomatic patients of chronic obstructive pulmonary disease in China. Chin Med J (Engl) (2010) 1.62
Planar cell polarity signaling in vertebrates. Bioessays (2007) 1.62
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell (2012) 1.61
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res (2006) 1.61
A conserved mechanism of bract suppression in the grass family. Plant Cell (2010) 1.59
Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem (2002) 1.59
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Validity of Asthma Control Test in Chinese patients. Chin Med J (Engl) (2007) 1.58
Duplicate FLORICAULA/LEAFY homologs zfl1 and zfl2 control inflorescence architecture and flower patterning in maize. Development (2003) 1.58
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood (2006) 1.55
Conservation of B-class floral homeotic gene function between maize and Arabidopsis. Development (2004) 1.55
Barriers to TB care for rural-to-urban migrant TB patients in Shanghai: a qualitative study. Trop Med Int Health (2009) 1.53
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol (2008) 1.53
Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther (2007) 1.53
Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology (2010) 1.50
Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer. Clin Lung Cancer (2009) 1.50
Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem (2002) 1.50
Cochlear gap junctions coassembled from Cx26 and 30 show faster intercellular Ca2+ signaling than homomeric counterparts. Am J Physiol Cell Physiol (2005) 1.49
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun (2012) 1.49
Substrate-friendly synthesis of metal oxide nanostructures using a hotplate. Small (2006) 1.45
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther (2007) 1.45
Expression of Islet1 marks the sensory and neuronal lineages in the mammalian inner ear. J Comp Neurol (2004) 1.45